Tifeglipron for Type 2 Diabetes

A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes

Recruiting Phase 2 Interventional Study
Type 2 Diabetes Mellitus
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
330 (estimated)
Sponsor
Hoffmann-La Roche · Industry
Who this trial is looking for

This trial is looking for adults with type 2 diabetes to test different doses of a medication called tifeglipron. Participants will help researchers understand how well this treatment works and how safe it is.

Are You a Good Fit for This Trial?
Must be taking MetforminSGLT-2 inhibitors
Rules you out Type 1 diabetesSevere low blood sugarProliferative diabetic retinopathyDiabetic macular edemaNephropathyNeuropathyObesity from endocrine disordersGastric emptying abnormality

You may be able to join if

  • I have been diagnosed with type 2 diabetes
  • I have an HbA1c between 7% and 10.5%
  • I manage my diabetes with diet and exercise or with metformin or SGLT-2 inhibitors
  • My body mass index (BMI) is 23.0 or higher
  • My weight has been stable for the last 3 months

You may not be able to join if

  • I have type 1 diabetes or any other type of diabetes
  • I have had severe low blood sugar or do not recognize low blood sugar symptoms in the last 6 months
  • I have serious eye problems from diabetes that need emergency treatment
  • I have significant kidney or nerve problems
  • I have taken other diabetes medications in the last 3 months
  • I have obesity caused by other hormone disorders
  • I have known problems with stomach emptying
  • I have poorly controlled high blood pressure

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of different doses of tifeglipron for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Have a diagnosis of Type 2 diabetes mellitus (T2D) for at least 6 months before screening * Have an HbA1c ≥7% and ≤10.5% at screening * Management of T2D with diet and exercise alone or with either a stable dose of metformin or/and sodium-glucose cotransporter-2 (SGLT-2) inhib…
Contacts

Reference Study ID Number: BP45703 https://forpatients.roche.com/ No attachments to email below.

888-662-6728 (U.S. Only)

global-roche-genentech-trials@gene.com

CONTACT

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

CONTACT